We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+95.73%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$643M
AUM Growth
+$316M
Cap. Flow
+$95.3M
Cap. Flow %
14.83%
Top 10 Hldgs %
78.08%
Holding
44
New
3
Increased
4
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
CRGX
CARGO Therapeutics
CRGX
+$69.9M
2
SRRK icon
Scholar Rock
SRRK
+$27.2M
3
NGNE icon
Neurogene
NGNE
+$18.2M
4
ABVX
Abivax
ABVX
+$8.66M
5
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$3.1M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$11.9M
2
ACLX
Arcellx
ACLX
+$6.92M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$5.45M
4
IMCR icon
Immunocore
IMCR
+$4.2M
5
EYPT icon
EyePoint Inc
EYPT
+$3.45M

Sector Composition

Rank Sector Weight
1 Healthcare 99.57%
2 Financials 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PEPG icon
26
PepGen
PEPG
$197M
$2.97M 0.46%
436,813
-214,237
-33% -$1.17M
DAWN
27
DELISTED
Day One Biopharmaceuticals
DAWN
$2.87M 0.45%
196,425
– –
CYPH
28
Cypherpunk Technologies Inc
CYPH
$73.3M
$2.77M 0.43%
669,303
+67,100
+11% +$145K
RAIN
29
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$2.44M 0.38%
2,034,552
– –
TERN
30
DELISTED
Terns Pharmaceuticals
TERN
$1.31M 0.2%
202,348
– –
IGMS
31
DELISTED
IGM Biosciences
IGMS
$1.29M 0.2%
154,664
– –
BOLT icon
32
Bolt Biotherapeutics
BOLT
$7.78M
$1.18M 0.18%
52,458
– –
ACRS icon
33
Aclaris Therapeutics
ACRS
$869M
$731K 0.11%
696,171
– –
VTVT icon
34
vTv Therapeutics
VTVT
$139M
$470K 0.07%
40,888
– –
ALLK
35
DELISTED
Allakos
ALLK
$470K 0.07%
172,089
– –
VIRX
36
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$393K 0.06%
689,709
– –
SNCE
37
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$240K 0.04%
45,000
– –
KRON
38
DELISTED
Kronos Bio
KRON
$97.7K 0.02%
78,131
– –
KLRS
39
Kalaris Therapeutics
KLRS
$96.8M
$56K 0.01%
3,580
– –
NUVB.WS
40
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$8K ﹤0.01%
133,333
– –
SRZNW icon
41
Surrozen Inc Warrant
SRZNW
$8.86K
$1.94K ﹤0.01%
99,999
– –
EYPT icon
42
EyePoint Inc
EYPT
$1.2B
– –
-432,000
Closed -$3.45M
IMCR icon
43
Immunocore
IMCR
$1.73B
– –
-80,963
Closed -$4.2M
ICPT
44
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-640,688
Closed -$11.9M
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q4 2023 Portfolio in Review

As of Q4 2023, Samsara BioCapital held 44 positions worth $643M, up 97% from $327M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Samsara BioCapital deployed $95.3M of net new capital in Q4 2023, opening 3 new positions and adding to 4 existing holdings. Its largest new stake was CARGO Therapeutics: 4,121,689 shares worth $95.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcellx, an estimated $6.92M trimmed.

  • Samsara BioCapital's largest Q4 2023 buy was CARGO Therapeutics: 4,121,689 shares worth $95.4M.
  • Samsara BioCapital added most to Scholar Rock in Q4 2023, an estimated $27.2M increase.
  • Samsara BioCapital's biggest Q4 2023 reduction was Arcellx, cutting an estimated $6.92M.
  • Samsara BioCapital fully exited Intercept Pharmaceuticals, Inc. in Q4 2023, selling an estimated $11.9M.
  • Samsara BioCapital's ten largest holdings make up 78% of its $643M portfolio in Q4 2023.
  • Samsara BioCapital opened 3 new positions and closed 3 in Q4 2023.
  • Samsara BioCapital's portfolio value rose 97% quarter-over-quarter to $643M.

Based on Samsara BioCapital's 13F filing for Q4 2023, filed 14 Feb 2024.